Sienna Biopharmaceuticals Inc. (SNNAQ)
OTC PINK OTC PINK Primary Summary
Sienna Biopharmaceuticals Inc. (SNNAQ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sienna Biopharmaceuticals Inc. ever had a stock split?
Sienna Biopharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | David E. I. Pyott CEO | OTC PINK Exchange | 82622H108 CUSIP |
| US Country | 13 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Sienna Biopharmaceuticals, Inc. was a clinical-stage biopharmaceutical company engaged in the development of drugs across a variety of therapeutic areas, with a specific focus on immunology and inflammation, targeting select pathways in tissues such as the skin. Originally founded in 2010 as Sienna Labs, Inc., the company underwent a name change to Sienna Biopharmaceuticals, Inc. in February 2016, positioning itself in Westlake Village, California. Despite its innovative approach to developing therapeutic solutions, Sienna Biopharmaceuticals faced financial difficulties, leading to a Chapter 11 bankruptcy filing on September 16, 2019, which was later converted to Chapter 7 on December 18, 2019, marking the termination of its operations.
Products and Services
- SNA-120
- SNA-125
- SNA-001
A pioneering inhibitor of tropomyosin receptor kinase A, SNA-120 was positioned as a first-of-its-kind therapeutic for the treatment of psoriasis and the associated pruritus. Undergoing a Phase IIb clinical trial, SNA-120 aimed to offer a novel approach to managing these debilitating skin conditions by targeting underlying pathways.
This product represented a dual action, targeting Janus kinase 3 with topical application. It was in the midst of Phase I/II clinical trials, offering potential relief for individuals suffering from atopic dermatitis, psoriasis, and pruritus. SNA-125's innovative formulation sought to provide a multifaceted approach to treatment, combining efficacy with topical convenience.
With a distinct approach, SNA-001 involved a topical suspension of silver particles, advancing into pivotal clinical trials for two purposes: treating acne and reducing light-pigmented hair (inclusive of white, gray, blonde, light brown, and light red hair). This product highlighted Sienna Biopharmaceuticals' commitment to diversifying its therapeutic portfolio by venturing into dermatological and cosmetic applications.
